A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19.

Humans COVID-19 Demeclocycline RNA, Viral SARS-CoV-2

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
23 08 2023
Historique:
received: 08 03 2023
accepted: 21 08 2023
medline: 25 8 2023
pubmed: 24 8 2023
entrez: 23 8 2023
Statut: epublish

Résumé

Tetracyclines exhibit anti-viral, anti-inflammatory, and immunomodulatory activities via various mechanisms. The present study investigated the efficacy and safety of demeclocycline in patients hospitalized with mild-to-moderate COVID-19 via an open-label, multicenter, parallel-group, randomized controlled phase 2 trial. Primary and secondary outcomes included changes from baseline (day 1, before the study treatment) in lymphocytes, cytokines, and SARS-CoV-2 RNA on day 8. Seven, seven, and six patients in the control, demeclocycline 150 mg daily, and demeclocycline 300 mg daily groups, respectively, were included in the modified intention-to-treat population that was followed until day 29. A significant change of 191.3/μL in the number of CD4

Identifiants

DOI: 10.1038/s41598-023-41051-2 PMID: 37612352 PMC: PMC10447520
pubmed: 37612352
doi: 10.1038/s41598-023-41051-2
pii: 10.1038/s41598-023-41051-2
pmc: PMC10447520
doi:

Substances chimiques

Demeclocycline 5R5W9ICI6O
RNA, Viral 0
diflumidone E96467495S

Types de publication

Clinical Trial, Phase II Randomized Controlled Trial Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13809

Informations de copyright

© 2023. Springer Nature Limited.

Références

Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615. https://doi.org/10.1056/NEJMoa2034577 (2020).
doi: 10.1056/NEJMoa2034577 pubmed: 33301246
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416. https://doi.org/10.1056/NEJMoa2035389 (2021).
doi: 10.1056/NEJMoa2035389 pubmed: 33378609
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 (2021).
doi: 10.1016/S0140-6736(20)32661-1 pubmed: 33306989 pmcid: 7723445
Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201. https://doi.org/10.1056/NEJMoa2101544 (2021).
doi: 10.1056/NEJMoa2101544 pubmed: 33882225
Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172–1183. https://doi.org/10.1056/NEJMoa2107659 (2021).
doi: 10.1056/NEJMoa2107659 pubmed: 34192426
Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—Final report. N. Engl. J. Med. 383, 1813–1826. https://doi.org/10.1056/NEJMoa2007764 (2020).
doi: 10.1056/NEJMoa2007764 pubmed: 32445440
Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386, 1397–1408. https://doi.org/10.1056/NEJMoa2118542 (2022).
doi: 10.1056/NEJMoa2118542 pubmed: 35172054
Jayk Bernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386, 509–520. https://doi.org/10.1056/NEJMoa2116044 (2022).
doi: 10.1056/NEJMoa2116044 pubmed: 34914868
Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–1950. https://doi.org/10.1056/NEJMoa2107934 (2021).
doi: 10.1056/NEJMoa2107934 pubmed: 34706189
Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81. https://doi.org/10.1056/NEJMoa2108163 (2021).
doi: 10.1056/NEJMoa2108163 pubmed: 34587383
Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384, 229–237. https://doi.org/10.1056/NEJMoa2029849 (2021).
doi: 10.1056/NEJMoa2029849 pubmed: 33113295
Dougan, M. et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N. Engl. J. Med. 385, 1382–1392. https://doi.org/10.1056/NEJMoa2102685 (2021).
doi: 10.1056/NEJMoa2102685 pubmed: 34260849
Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N. Engl. J. Med. 384, 1491–1502. https://doi.org/10.1056/NEJMoa2100433 (2021).
doi: 10.1056/NEJMoa2100433 pubmed: 33631065
Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 384, 693–704. https://doi.org/10.1056/NEJMoa2021436 (2021).
doi: 10.1056/NEJMoa2021436 pubmed: 32678530
Kalil, A. C. et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 384, 795–807. https://doi.org/10.1056/NEJMoa2031994 (2021).
doi: 10.1056/NEJMoa2031994 pubmed: 33306283
Bertoletti, A., Le Bert, N. & Tan, A. T. SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic. Immunity 55, 1764–1778. https://doi.org/10.1016/j.immuni.2022.08.008 (2022).
doi: 10.1016/j.immuni.2022.08.008 pubmed: 36049482 pmcid: 9385766
Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19. Nat. Med. 26, 453–455. https://doi.org/10.1038/s41591-020-0819-2 (2020).
doi: 10.1038/s41591-020-0819-2 pubmed: 32284614 pmcid: 7095036
Wang, F. et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J. Infect. Dis. 221, 1762–1769. https://doi.org/10.1093/infdis/jiaa150 (2020).
doi: 10.1093/infdis/jiaa150 pubmed: 32227123
Garrido-Mesa, J., Adams, K., Galvez, J. & Garrido-Mesa, N. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: A critical discussion of recent publications. Expert Opin. Investig. Drugs 31, 475–482. https://doi.org/10.1080/13543784.2022.2054325 (2022).
doi: 10.1080/13543784.2022.2054325 pubmed: 35294307 pmcid: 9115781
Gendrot, M. et al. In vitro antiviral activity of doxycycline against SARS-CoV-2. Molecules https://doi.org/10.3390/molecules25215064 (2020).
doi: 10.3390/molecules25215064 pubmed: 33142770 pmcid: 7663271
Hoyt, J. C., Ballering, J., Numanami, H., Hayden, J. M. & Robbins, R. A. Doxycycline modulates nitric oxide production in murine lung epithelial cells. J. Immunol. 176, 567–572. https://doi.org/10.4049/jimmunol.176.1.567 (2006).
doi: 10.4049/jimmunol.176.1.567 pubmed: 16365451
Kim, H. S., Luo, L., Pflugfelder, S. C. & Li, D. Q. Doxycycline inhibits TGF-beta1-induced MMP-9 via Smad and MAPK pathways in human corneal epithelial cells. Investig. Ophthalmol. Vis. Sci. 46, 840–848. https://doi.org/10.1167/iovs.04-0929 (2005).
doi: 10.1167/iovs.04-0929
Butler, C. C. et al. Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): A randomised, controlled, open-label, adaptive platform trial. Lancet Respir. Med. 9, 1010–1020. https://doi.org/10.1016/S2213-2600(21)00310-6 (2021).
doi: 10.1016/S2213-2600(21)00310-6 pubmed: 34329624 pmcid: 8315758
Noguchi, Y. et al. Tetracyclines enhance anti-tumor T-cell responses induced by a bispecific T-cell engager. Biol. Pharm. Bull. 45, 429–437. https://doi.org/10.1248/bpb.b21-00806 (2022).
doi: 10.1248/bpb.b21-00806 pubmed: 35370267
Tarke, A. et al. Early and polyantigenic CD4 T cell responses correlate with mild disease in acute COVID-19 donors. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23137155 (2022).
doi: 10.3390/ijms23137155 pubmed: 35806161 pmcid: 9267033
Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728. https://doi.org/10.1016/j.celrep.2021.108728 (2021).
doi: 10.1016/j.celrep.2021.108728 pubmed: 33516277 pmcid: 7826084
RydyznskiModerbacher, C. et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 183, 996-1012.e1019. https://doi.org/10.1016/j.cell.2020.09.038 (2020).
doi: 10.1016/j.cell.2020.09.038
Belaid, B. et al. T cell counts and IL-6 concentration in blood of North African COVID-19 patients are two independent prognostic factors for severe disease and death. J. Leukoc. Biol. 111, 269–281. https://doi.org/10.1002/JLB.4COVA1020-703R (2022).
doi: 10.1002/JLB.4COVA1020-703R pubmed: 33527487
Diao, B. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827. https://doi.org/10.3389/fimmu.2020.00827 (2020).
doi: 10.3389/fimmu.2020.00827 pubmed: 32425950 pmcid: 7205903
Liu, T. et al. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol. Med. 12, e12421. https://doi.org/10.15252/emmm.202012421 (2020).
doi: 10.15252/emmm.202012421 pubmed: 32428990 pmcid: 7280589
Steenblock, C. et al. COVID-19 and metabolic disease: Mechanisms and clinical management. Lancet Diabetes Endocrinol. 9, 786–798. https://doi.org/10.1016/S2213-8587(21)00244-8 (2021).
doi: 10.1016/S2213-8587(21)00244-8 pubmed: 34619105 pmcid: 8489878

Auteurs

Kota Iwahori (K)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. iwahori@climm.med.osaka-u.ac.jp.
Department of Clinical Research in Tumor Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. iwahori@climm.med.osaka-u.ac.jp.

Takuro Nii (T)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Norihiko Yamaguchi (N)

Department of Respiratory Medicine, Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan.

Takahiro Kawasaki (T)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Satomi Okamura (S)

Department of Medical Innovation, Osaka University Hospital, Suita, Osaka, Japan.

Kazuki Hashimoto (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Takanori Matsuki (T)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Kazuyuki Tsujino (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Keisuke Miki (K)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Akio Osa (A)

Department of Respiratory Medicine, Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan.

Sho Goya (S)

Department of Respiratory Medicine, Kinki Central Hospital of Mutual Aid Association of Public School Teachers, Itami, Hyogo, Japan.

Kinya Abe (K)

Department of Internal Medicine, Toyonaka Municipal Hospital, Toyonaka, Osaka, Japan.

Masahide Mori (M)

Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Yoshito Takeda (Y)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.

Tomomi Yamada (T)

Department of Medical Innovation, Osaka University Hospital, Suita, Osaka, Japan.

Hiroshi Kida (H)

Department of Respiratory Medicine, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Osaka, Japan.

Atsushi Kumanogoh (A)

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Department of Immunopathology, World Premier International Research Center Initiative (WPI), Immunology Frontier Research Center (IFReC), Osaka University, Suita, Osaka, Japan.
Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka, Japan.
Center for Infectious Diseases for Education and Research (CiDER), Osaka University, Suita, Osaka, Japan.
Japan Agency for Medical Research and Development-Core Research for Evolutional Science and Technology (AMED-CREST), Osaka University, Suita, Osaka, Japan.
Center for Advanced Modalities and DDS (CAMaD), Osaka University, Suita, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A randomized phase 2 study on demeclocycline...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › A randomized phase 2 study on demeclocycline...
questionsmedicales.fr › Composés polycycliques › Hydrocarbures aromatiques polycycliques › Naphtacènes › Tétracyclines › Déméclocycline › A randomized phase 2 study on demeclocycline...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN viral › A randomized phase 2 study on demeclocycline...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › A randomized phase 2 study on demeclocycline...